Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Eating Well (or at Least Not terribly) at Fast Food Resturants
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

World Diabetes Day 2009

DHTV Covers World Diabetes Day in Sacramento, California

World Diabetes Day 2009

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

A Product For When You Have Low Blood Sugar

Bill Abajian

A Product For When You Have Low Blood Sugar

View all Videos…
Exenatide Archives
Browse the Exenatide Archives
Subscribe to the Medications RSS Feed

Exenatide

Medications RSS Feed RSS
Updated 32 weeks ago
 
Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs
news
Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

Comments 0 comments - Nov 5, 2012 - * * * * *

An Update on Bydureon
blog
An Update on Bydureon

You've heard of the blockbuster drug Byetta, a daily injection for type 2 diabetes? Byetta's sister product, Bydureon, which is injected just once a week, has just been approved by the FDA and is available in pharmacies.

Comments 13 comments - Feb 17, 2012 - * * * * *

FDA Gives Long-Awaited Nod to Amylin’s Bydureon
news
FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.

Comments 2 comments - Feb 3, 2012 - * * * * *

 
©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.